Category - Developments

Developments

Imagin Medical updates i/Blue’s functional unit development

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) provided an update on its progress towards verifying the i/Blue imaging system’s functional prototype. The company has integrated the i/Blue...

July 15, 2019

Developments

Kadmon Holdings doses first patient in Phase 2 systemic sclerosis trial

Kadmon Holdings (NYSE:KDMN) dosed the first patient in its Phase 2 clinical trial of KD025 in patients with diffuse cutaneous systemic sclerosis (SSc). SSc is a chronic immune disease characterized by fibrosis of the...

July 11, 2019

Developments

GMP adds Zenabis Global to Best Ideas list

GMP Securities added Zenabis Global (TSX:ZENA) to its Best Ideas list, saying its sees the company becoming a top five Canadian licensed producer of cannabis but with a valuation well below most of its peers. Analyst...

July 10, 2019

Developments

Profound Medical sells first TULSA-PRO system in Japan

Profound Medical (TSX:PRN; OTCQX:PRFMF) sold its first TULSA-PRO system to Hokuyu Hospital in Sapporo through Japan’s Pharmaceutical and Medical Device (PMD) Act’s expanded access program. Japan’s Pharmaceutical...

July 10, 2019

Developments

Trovagene initiates Phase 1b/2 trial of ovansertib in colorectal cancer

Trovagene (NASDAQ:TROV) began enrollment for its Phase 1b/2 study of onvansertib for the treatment of patients with metastatic colorectal cancer (mCRC). The trial will assess the safety and efficacy of onvansertib, in...

July 9, 2019

Developments

Titan Pharma and CVS Caremark enter Probuphine distribution agreement

Titan Pharmaceuticals (NASDAQ:TTNP) signed a specialty product distribution agreement with CVS Caremark, a subsidiary of CVS Health, further expanding access to treatment with Probuphine implant, Titan’s novel...

July 9, 2019

Developments

Zenabis submits site evidence package to Health Canada for Langley facility

Zenabis Global Inc. (TSX:ZENA)submitted its site evidence package to Health Canada for the first phase of Site A at its Zenabis Langley plant.

July 9, 2019

Developments

Pulmatrix opens three Phase 2 clinical trial sites for inhaled anti-fungal

Pulmatrix (NASDAQ:PULM) activated three U.S. sites for its Phase 2 clinical trial of pulmazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma. The primary objective of the...

July 9, 2019

Developments

Tilray expands European team with five senior appointments

Tilray (NASDAQ:TLRY) welcomed five individuals to its leadership team to support the company’s aggressive European and international expansion strategy. Tilray appointed Arne Wilkens as VP business expansion; José...

July 8, 2019

Developments

Bellicum Pharma rivo-cel hits primary endpoint in pivotal trial

Bellicum Pharmaceuticals’ (NASDAQ:BLCM) registrational trial of rivo-cel achieved its primary endpoint of event-free survival when the drug was administered to patients receiving stem cell transplants.

July 8, 2019

Category - Developments

Subscribe